Adaptimmune

URI: https://gptkb.org/entity/Adaptimmune

GPTKB entity

Statements (69)

Predicate	Object
gptkbp:instance_of	gptkb:biotechnology
gptkbp:acquisition	gptkb:none
gptkbp:advocacy	engaged
gptkbp:business_model	biotech
gptkbp:can_lead_to	gptkb:ADP-A2_AFP gptkb:ADP-A2_M4
gptkbp:ceo	gptkb:Gareth_Evans
gptkbp:clinical_trial	gptkb:Oncology gptkb:public_company ongoing Phase 1 multiple locations Phase 2 Phase 3 innovative published promising solid tumors overall survival progression-free survival
gptkbp:collaboration	gptkb:University_of_Pennsylvania
gptkbp:collaborations	ongoing pharmaceutical companies biopharmaceutical companies various academic institutions
gptkbp:conference	participates
gptkbp:employees	over 100
gptkbp:focus	gptkb:CAR_T-cell_therapy
gptkbp:founded	gptkb:2008
gptkbp:founder	gptkb:James_Noble
gptkbp:funding	gptkb:venture_capital grants
gptkbp:has_advisory_board	established
gptkbp:headquarters	gptkb:Oxford,_United_Kingdom
gptkbp:healthcare	focused
https://www.w3.org/2000/01/rdf-schema#label	Adaptimmune
gptkbp:instruction_set	gptkb:ADP-A2_AFP gptkb:ADP-A2_M4 ADP-A2 M4 CD8
gptkbp:invention	multiple
gptkbp:investment	gptkb:significant active institutional investors high.
gptkbp:investment_focus	immuno-oncology
gptkbp:is_tested_for	identified
gptkbp:marketing_strategy	gptkb:expansion growth-oriented
gptkbp:partnership	gptkb:GSK
gptkbp:partnerships	various
gptkbp:patient_population	diverse
gptkbp:philosophy	personalized medicine
gptkbp:publications	numerous
gptkbp:reach	international
gptkbp:regulatory_compliance	gptkb:FDA frequent
gptkbp:research	cutting-edge
gptkbp:research_areas	multiple oncology accelerated
gptkbp:research_focus	engineered T-cell therapies
gptkbp:stock_exchange	gptkb:NASDAQ
gptkbp:stock_symbol	ADAP
gptkbp:targets	cancer cells
gptkbp:technology	SPEAR T-cell platform
gptkbp:therapeutic_strategy	targeted therapy
gptkbp:website	www.adaptimmune.com
gptkbp:bfsParent	gptkb:Agenus_Inc.
gptkbp:bfsLayer	5